Zyngenia is developing a new class of biotherapeutics that better address the complexity of diseases by the simultaneous targeting of multiple physiologic pathways. These highly specific, single molecule drugs are able to more effectively treat multi-factorial diseases such as cancer, inflammation and autoimmune disorders.
The Company's pipeline is comprised of monoclonal antibody (mAb)-based drugs that are able to concomitantly engage several validated disease targets through the genetic fusion of additional peptide binding motifs to the mAb. Zyngenia has advanced three programs into preclinical development and achieved preclinical proof-of-concept with both bi-specific and tri-specific programs in cancer and inflammation.